

21. Feng Z, Zhang Y, Chen D, et al. Causal relationship between gut microbiota and kidney diseases: a two-sample Mendelian randomization study. *Front Immunol.* 2023;14:1277554. [Internet]. 2023 Jan 12 [cited 2025 Dec 7]. Available from: <https://gwas.mrcieu.ac.uk/>.
22. Kim MG, Cho WY, Park MS, et al. Altered gut microbiome plays an important role in AKI to CKD transition in aged mice. *Front Med (Lausanne).* 2023;10:1238960. [Internet]. 2023 Oct 31 [cited 2025 Dec 7]. Available from: <http://www.bio-protocol.org/e1289>.
23. Holle J, Reitmeir R, Potapenko O, et al. Gut microbiome alterations precede graft rejection in kidney transplantation patients. *Am J Transplant.* 2025;25(8):1643-1656.
24. Kim YC, Sohn KH, Kang HR. Gut microbiota dysbiosis and its impact on asthma and other lung diseases: potential therapeutic approaches. *Korean J Intern Med.* 2024;39(5):746.
25. Tanevska E, Leyton CE, Seamark R. The usefulness of microbiome profiling for geriatric patients with neuropsychiatric conditions: a scoping review. *Transl Psychiatry.* 2025;15(1):420.
26. Seo D oh, Holtzman DM. Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies. *Exp Mol Med.* 2024;56(1):86-94.
27. Eytting M, Xie M, Geldsetzer P, et al. A natural experiment on the effect of herpes zoster vaccination on dementia. *Nature.* 2025;641(8062):438-446.
28. Fliegerová KO, Mahayri TM, Jarošiková R, et al. Diabetes and gut microbiome. *Front Microbiol.* 2024;15:1451054.
29. Deng X, Zhang C, Wang P, et al. Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes. *J Clin Endocrinol Metab.* 2022;107(7):1888-1896. [Internet]. 2022 Jun 16 [cited 2025 Dec 7]. Available from: <https://dx.doi.org/10.1210/clinem/dgac210>.
30. Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. *Clin Exp Immunol.* 2022;209(2):161-174. [Internet]. 2022 Aug 19 [cited 2025 Dec 8]. Available from: <https://dx.doi.org/10.1093/cei/uxac057>.
31. Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. *Nat Rev Endocrinol.* 2023;19(8):460-476. [Internet]. 2023 May 2 [cited 2025 Dec 7]. Available from: <https://www.nature.com/articles/s41574-023-00833-4>.
32. Routy B, Le Chatelier E, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science.* 2018;359(6371):91-97. [Internet]. 2018 Jan 5 [cited 2025 Dec 7]. Available from: <https://www.science.org/doi/10.1126/science.aan3706>.
33. Kumar A, Sun R, Palm NW, et al. Identification of medication-microbiome interactions that affect gut infection. *Nature.* 2025;644(8076):506-515. [Internet]. 2025 Jul 16 [cited 2025 Dec 7]. Available from: <https://www.nature.com/articles/s41586-025-09273-8>.
34. Aasmets O, Taba N, Metspalu M, et al. A hidden confounder for microbiome studies: medications used years before sample collection. *mSystems.* 2025;???. [Internet]. 2025 Oct 22 [cited 2025 Dec 7]. Available from: <https://journals.asm.org/doi/10.1128/msystems.00541-2>.

# AI-dialogy: KDYŽ MEDICÍNA MLUVÍ NAPŘÍČ OBORY

Spojili jsme sílu odborných dat a umělé inteligence, abychom vám přinesli **podcasty, které vzdělávají, inspirují a šetří čas.**



Rozšiřte si obzory poslechem podcastů s mezioborovým zaměřením.



AI-generované podcasty přinášejí to, co právě rezonuje v médiích i odborných kruzích – témata, která překračují hranice specializací a inspirují k novému pohledu na péči o pacienta.

